You could be what ties MOG‑AD research together
Introducing cosMOG: a clinical research study for people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOG‑AD)
Introducing cosMOG: a clinical research study for people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOG‑AD)
The cosMOG study aims to understand how well-tolerated and effective an investigational drug called rozanolixizumab is in people with MOG‑AD. The investigational drug will be given weekly as an infusion under the skin.
With no approved treatment options for MOG‑AD, we understand that your treatment journey may not have been an easy one. Clinical research studies, also called clinical trials, are a necessary and vital step toward understanding rare diseases such as MOG‑AD and how to treat them.
With your help, the cosMOG study will evaluate if an investigational drug can prolong the time between relapses for people with this condition.
Learn more about this studyYou may be eligible to take part in the cosMOG study if you (among other things):
© 2023 UCB Biopharma SRL, Belgium. All rights reserved.
MOG001_Study Website_USA ENG_V2_25Apr23
This site is intended for US audiences only.
Share
Copy page link
Send from your email account
